CELGENE CORPORATION (NASDAQ:CELG) Files An 8-K Other Events
ITEM 8.01
| OTHER EVENTS |
On April 3, 2017, Celgene Corporation announced it has received a
Paragraph IV Notice Letter advising that Teva Pharmaceuticals
USA, Inc. submitted an Abbreviated New Drug Application (ANDA) to
the U.S. Food and Drug Administration (FDA) seeking authorization
from the FDA to manufacture and market a generic version of
POMALYST (pomalidomide) 1 mg, 2 mg, 3 mg and 4 mg in the United
States.
The Notice Letter contains Paragraph IV certifications against
certain of Celgenes patents related to POMALYST. Celgene intends
to vigorously defend its extensive intellectual property rights
related to POMALYST.
Attached hereto and incorporated herein by reference as
Exhibit99.1 is the Press Release announcement.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS. |
Exhibit99.1 Press Release dated April 3, 2017
EXHIBIT INDEX
| ExhibitNo. | Description | |
| 99.1 | Press Release dated April 3, 2017. |
About CELGENE CORPORATION (NASDAQ:CELG)
Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation. The Company’s primary commercial stage products include REVLIMID (lenalidomide), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), POMALYST/IMNOVID (pomalidomide), VIDAZA, azacitidine for injection (generic version of VIDAZA), THALOMID (thalidomide), OTEZLA (apremilast) and ISTODAX (romidepsin). The Company’s clinical trial activity includes trials across the disease areas of hematology, oncology, and inflammation and immunology. CELGENE CORPORATION (NASDAQ:CELG) Recent Trading Information
CELGENE CORPORATION (NASDAQ:CELG) closed its last trading session down -0.38 at 124.05 with 3,728,614 shares trading hands.
